Safety First: Perspective on Patient-Centered Development of AAV Gene Therapy Products
- PMID: 29503193
- PMCID: PMC5911637
- DOI: 10.1016/j.ymthe.2018.02.009
Safety First: Perspective on Patient-Centered Development of AAV Gene Therapy Products
Comment on
-
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.Hum Gene Ther. 2018 Mar;29(3):285-298. doi: 10.1089/hum.2018.015. Epub 2018 Feb 12. Hum Gene Ther. 2018. PMID: 29378426 Free PMC article.
-
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice.Mol Ther. 2018 Mar 7;26(3):664-668. doi: 10.1016/j.ymthe.2018.01.018. Epub 2018 Feb 2. Mol Ther. 2018. PMID: 29428298 Free PMC article.
References
-
- FDA (1996). Guidance for industry E6 good clinical practice: consolidated guidance. https://www.fda.gov/downloads/drugs/guidances/ucm073122.pdf.
-
- Flotte T.R., Buning H. Severe toxicity in nonhuman primates and piglets with systemic high-dose administration of adeno-associated virus serotype 9-like vectors: putting patients first. Hum. Gene Ther. 2018 Published online February 7, 2018. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
